Bimekizumab maintained efficacy responses through 52 weeks in biologic diseasemodifying antirheumatic drug-naive patients with psoriatic arthritis who were responders at week 16: results from be optimal, a phase 3, active-reference study
ANNALS OF THE RHEUMATIC DISEASES(2023)
Key words
Psoriatic arthritis,Clinical trials
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined